Remsima SC Achieves 22% Market Share in Europe... Grows More Than Fivefold in Four Years

Remsima Product Group (IV and SC) Achieves 71% Market Share in Europe

Remsima SC, Celltrion's infliximab subcutaneous (SC) formulation and the only one of its kind in the world, recorded a 22% market share across Europe as of the end of last year.

Remsima SC. Celltrion

According to IQVIA, a pharmaceutical market research firm, on May 28, Remsima SC had only a 4% share of the European market in 2021, its first year of sales following its 2020 launch in Europe. Over four years, its market share has increased more than fivefold.

In particular, when combining sales of the intravenous (IV) formulation Remsima, the entire Remsima product group achieved a 71% market share in Europe as of the end of last year. This means that 7 out of 10 patients with autoimmune diseases prescribed infliximab in Europe are being treated with the Remsima product group.

The outlook for sales of Zymfentra (the US brand name for Remsima SC), currently available in the United States, is also positive. Celltrion believes that, given the period of prescription stabilization achieved by Remsima SC in Europe, prescriptions for Zymfentra in the US will accelerate once it is included in the formularies of major insurance companies.

Other Celltrion therapies for autoimmune diseases are also performing well in Europe. The adalimumab biosimilar Yuflyma recorded a 21% market share in Europe as of the end of last year.

Stekyma, the ustekinumab biosimilar launched in Europe in October last year, increased its market share by more than 2 percentage points within just two months of sales, successfully securing an early lead in the market. This success is attributed to the implementation of tailored sales strategies by local subsidiaries established in major European countries, which aligned with the unique characteristics of each national pharmaceutical market.

Celltrion's products are also achieving strong results in its main target area of oncology. Vegzelma, launched in Europe in the second half of 2022, achieved a 28% market share as of the end of last year, ranking first in prescriptions among nine bevacizumab products (including the original) available in Europe. The oncology drugs Truxima and Herzuma are also maintaining stable prescription trends in Europe, with market shares close to 30%.

A Celltrion representative stated, "The influence of Remsima SC is expanding rapidly in Europe, thanks to factors such as dosing convenience, therapeutic efficacy, and tailored sales strategies led by local subsidiaries. We expect these achievements to have a positive impact in the United States, the world's largest pharmaceutical market. With existing products already leading prescriptions in Europe, we plan to continue our performance growth this year by launching new biosimilar products in the second half."